Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems-Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)-in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
Methods: We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan-Meier curves, Cox proportional hazards models, time-dependent ROC curves, and random survival forest models.
Results: The median follow-up was 29 months (IQR: 25.96-32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression-free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune-related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS.
Conclusion: LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010209 | PMC |
| http://dx.doi.org/10.1002/hsr2.70713 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The dynamic nature of frailty in metastatic spine disease patients.
J Neurooncol
September 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Purpose: Frailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.
Methods: This retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI).
DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial.
J Cancer Res Clin Oncol
September 2025
Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.
Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.
View Article and Find Full Text PDFEnhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
J Thorac Oncol
September 2025
Institut du Thorax Curie-Montsouris, Paris, France; Paris-Saclay University, UVSQ-Versailles, France.
Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.
View Article and Find Full Text PDFReal-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.
Purpose: WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor () exon 20 insertion mutations (exon20ins).
Methods: Eligible patients with advanced-stage exon20ins NSCLC were randomly assigned by 1:1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts).